The Federal Hemp Redefinition: What Changes in November 2026

The federal definition of hemp is scheduled to change on November 12, 2026, narrowing which cannabinoid products qualify for hemp’s exemption from federal controlled-substance law.

The change reaches beyond products marketed for intoxicating effects. It also creates important questions for CBD brands, retailers, laboratories, and consumers—particularly where products contain trace THC or cannabinoids manufactured through chemical conversion.

As of 2026, the key reference is Public Law 119-37, enacted on November 12, 2025. Section 781 changes the federal hemp definition after a one-year implementation period. Congress.gov publishes the enacted text.

That distinction matters: this is an enacted change with a scheduled effective date, not simply a proposed rule. However, further legislation or implementation guidance could affect the practical outcome. Readers should check current federal developments and their own state’s law before making purchasing or business decisions.

Why the federal definition matters

The Agriculture Improvement Act of 2018, commonly called the 2018 Farm Bill, defined hemp as Cannabis sativa L. and its derivatives with a delta-9 THC concentration of no more than 0.3% on a dry-weight basis.

Qualifying hemp was removed from the federal Controlled Substances Act’s definition of marijuana. That distinction helped establish the modern hemp marketplace.

But the definition did not make every hemp-derived product lawful in every setting. The FDA retained authority over foods, dietary supplements, cosmetics, and drugs. States also retained substantial regulatory authority.

The November 2026 change tightens the threshold question: Does a plant, ingredient, or finished product qualify as hemp under federal law at all?

Passing that test still does not settle every other compliance question.

What changes in November 2026?

### Total THC replaces the narrower statutory delta-9 measure

The amended definition uses total tetrahydrocannabinols, including tetrahydrocannabinolic acid, or THCA, rather than relying only on the earlier statutory reference to delta-9 THC.

THCA is relevant because it can convert into THC when heated. Products cannot necessarily qualify as hemp merely because their measured delta-9 THC content is low before heating.

There is an important historical nuance here. USDA hemp-production rules already require testing that accounts for potential conversion of THCA into THC. The new statutory language therefore should not be described as the first time federal hemp oversight has considered THCA.

Instead, it makes total THC explicit in the amended definition and accompanies additional restrictions on cannabinoid products.

### Finished products face a per-container limit

The law excludes final hemp-derived cannabinoid products containing more than 0.4 milligrams per container of a specified combined total.

That total includes:

• Total tetrahydrocannabinols, including THCA.
• Other cannabinoids determined by the Secretary of Health and Human Services to have similar effects, or marketed as having similar effects, on humans or animals.

This is not a 0.4-milligram limit on CBD itself. Nor is it simply a limit per gummy, serving, or dropper.

The per-container structure is crucial. A small amount in each serving can accumulate across an entire bottle or package. A product that satisfied the earlier percentage-based definition may therefore fail the new finished-product standard.

For implementation, businesses must consult the statutory container definition and any relevant federal clarification rather than assuming that an individually portioned serving is the legally relevant container.

### Certain manufactured cannabinoids are excluded

The amended definition also excludes cannabinoid products containing cannabinoids that cannot occur naturally in the cannabis plant.

Separately, it excludes products containing cannabinoids that can occur naturally but were synthesized or manufactured outside the plant.

This makes production methods relevant—not just the name of the cannabinoid on the label. Chemical conversion processes may create compliance problems even when the resulting cannabinoid also occurs naturally in cannabis.

Ordinary extraction should not automatically be equated with chemical synthesis. Nevertheless, manufacturers need reliable process documentation and legal review rather than assuming that a hemp-derived starting material guarantees a qualifying finished ingredient.

Does this mean all CBD becomes federally illegal?

No. The enacted text does not impose a blanket prohibition on CBD.

The more accurate question is whether a particular CBD ingredient or product meets the revised definition, including its cannabinoid content, manufacturing history, and applicable product category.

A naturally extracted CBD product with sufficiently low covered cannabinoid content may present a different legal profile from a converted cannabinoid product or a CBD product containing measurable THC above the container limit.

At the same time, “non-intoxicating” is not a universal exemption. A product marketed without intoxicating effects can still fall outside the definition because of its composition.

Products excluded from the hemp definition lose that particular federal exemption. Their resulting legal status requires analysis under the Controlled Substances Act and other applicable laws; the answer should not be reduced to a slogan about all CBD being banned or all hemp-derived CBD remaining legal.

Why extract labels are not enough

Extract terminology offers useful context, but it does not replace testing.

Full-spectrum generally describes extracts containing a range of plant compounds, potentially including THC. Broad-spectrum generally describes extracts containing multiple plant compounds with THC removed. Isolate generally refers to a purified individual cannabinoid.

These are marketplace descriptions, not automatic federal compliance certifications.

Divine Earth’s products are broad-spectrum, with 0.0% THC. Even so, a 0.0% declaration should not be treated as a substitute for evaluating the applicable legal threshold and supporting laboratory records.

A reported percentage can involve rounding. A “not detected” result depends on the laboratory’s detection capability. Neither expression, standing alone, establishes precisely how many milligrams of covered cannabinoids are present in a complete container.

The practical priority is documentation: batch-specific testing, sufficiently sensitive methods, and clear product quantities.

What should consumers look for?

A certificate of analysis, often called a COA, becomes especially useful when it connects clearly to the product being purchased.

Look for:

• A matching batch number: The report should correspond to the actual product batch.
• A detailed cannabinoid panel: A CBD potency result alone does not establish THC compliance.
• Reporting limits: “Not detected” needs a stated analytical threshold.
• Clear units: Percentages and milligrams per gram must be interpreted alongside the container’s contents.
• Manufacturing transparency: Ingredient sourcing and production methods matter under the amended definition.

Consumers should not have to perform a regulatory audit themselves. A responsible brand should be able to explain its documentation without treating a marketing phrase as conclusive evidence.

There is also no sound basis for assuming that buying before November automatically resolves every question about possession, resale, or shipment afterward. Those activities can involve different federal and state rules.

What does not change automatically?

### FDA requirements remain separate

The FDA has consistently explained that the 2018 Farm Bill did not remove its authority over cannabis-derived ingredients.

Its published cannabis and CBD guidance identifies significant restrictions on adding CBD to foods introduced into interstate commerce and marketing CBD as a dietary supplement under the existing framework.

Consequently, meeting the revised hemp definition does not mean a product is FDA-approved or lawful in every product category. Cosmetic labeling, advertising, and other requirements also remain relevant.

### State laws still matter

Federal hemp status does not guarantee unrestricted sale in every state.

States may impose their own cannabinoid restrictions, licensing requirements, testing standards, age limits, or product-format rules. A state’s permission also cannot, by itself, preserve a federal hemp exemption that a product no longer meets.

Check current law where a product is sold, shipped, and used.

### Industrial hemp remains a distinct consideration

The legislation separately addresses industrial hemp uses, including specified fiber, grain, seed, and other non-cannabinoid applications.

It should therefore not be characterized as a prohibition on every hemp crop or hemp-based material. Cannabinoid products and industrial materials require different analysis.

The takeaway

The scheduled November 12, 2026 change replaces a comparatively broad hemp definition with tighter rules around total THC, finished-product container limits, and cannabinoid manufacturing.

For consumers, the most useful signals are transparent sourcing, meaningful batch testing, and clear explanations—not sweeping assurances of legality.

Use Congress.gov’s enacted text, USDA hemp resources, FDA guidance, and current state requirements as your starting points. Because implementation and legislation can change, verify the rules again before the effective date.